Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $19.33 Consensus Target Price from Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has earned a consensus recommendation of “Hold” from the six analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $19.33.

ENTA has been the topic of several analyst reports. StockNews.com lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, April 6th. JPMorgan Chase & Co. decreased their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Thursday, February 8th.

Enanta Pharmaceuticals Trading Down 1.7 %

ENTA stock opened at $12.92 on Friday. Enanta Pharmaceuticals has a 1-year low of $8.08 and a 1-year high of $37.75. The firm has a market cap of $273.34 million, a P/E ratio of -1.97 and a beta of 0.47. The business’s 50 day moving average is $14.85 and its 200-day moving average is $11.81.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. The company had revenue of $18.00 million during the quarter, compared to the consensus estimate of $22.74 million. Sell-side analysts forecast that Enanta Pharmaceuticals will post -4.9 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ENTA. Nisa Investment Advisors LLC lifted its holdings in Enanta Pharmaceuticals by 417.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,281 shares in the last quarter. Clearstead Advisors LLC acquired a new position in Enanta Pharmaceuticals during the 3rd quarter worth $57,000. Quantbot Technologies LP lifted its holdings in Enanta Pharmaceuticals by 2,300.0% during the 3rd quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock worth $80,000 after buying an additional 6,900 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new position in Enanta Pharmaceuticals during the 3rd quarter worth $113,000. Finally, Laurion Capital Management LP acquired a new position in Enanta Pharmaceuticals during the 3rd quarter worth $126,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.